Related Experiment Video
Updated: Jun 6, 2026
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
Published on: June 13, 2019
Molecular characterization of interdigitating dendritic cell sarcoma
Glen J Weiss1, Arlet Alarcon, Maqbool Halepota
1Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, USA.
Abstract:
Interdigitating dendritic cell sarcoma is an extremely rare cancer that lacks a standard treatment approach. We report on a patient who was surgically resected and remains disease- free. The tumor was assessed for druggable targets using immunohistochemical staining to identify potential agents that could be used in the event of disease recurrence.
Insights
Interdigitating dendritic cell sarcoma is a rare cancer with no standard treatment. This case study details a patient who achieved disease-free survival after surgical resection, with tumor targets identified for potential future therapies.
Area of Science:
- Oncology
- Surgical Pathology
Background:
- Interdigitating dendritic cell sarcoma (IDCS) is an exceptionally rare neoplasm.
- There is a lack of established treatment protocols for IDCS, necessitating novel therapeutic strategies.
Observation:
- A patient diagnosed with interdigitating dendritic cell sarcoma underwent surgical resection.
- The patient has remained disease-free following the surgical intervention.
Findings:
- Immunohistochemical staining was performed on the resected tumor.
- This analysis identified potential druggable targets within the tumor microenvironment.
Implications:
- The identification of druggable targets offers a potential avenue for future treatment in case of disease recurrence.
- This approach may guide personalized therapy for rare cancers like IDCS.
